Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma

Roberto Carmagnani Pestana, Manal M Hassan, Reham Abdelwahab Hassan Ali, Yehia I. Abugabal, Lauren M. Girard, Donghui Li, Ping Chang, Kanwal Pratap Singh Raghav, Jeffrey Morris, Robert A Wolff, Asif Rashid, Hesham Amin, Ahmed Kaseb

Research output: Contribution to journalArticle

Abstract

Angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) play critical roles in angiogenesis in hepatocellular carcinoma (HCC). In addition, recent data suggest that Ang-1/Ang-2 are involved in regulating the immune response. The aim of our study was to explore the clinical prognostic significance of plasma Ang-1 and Ang-2 in HCC. We prospectively enrolled and collected data and blood samples from 767 HCC patients treated at MD Anderson Cancer Center between 2001 and 2014. Controls consisted of cirrhotic patients (n = 75) and healthy volunteers (n = 200). The cutoff value was the median level of each angiogenic factor. Overall survival (OS) was estimated by Kaplan–Meier curves and compared by the log-rank test. Higher plasma Ang-2 was significantly associated with advanced clinicopathologic features of advanced HCC and lower OS. Median OS was 61.8 months (95% confidence interval [CI], 45.1–78.5 months) for low Ang-2 compared with 28.5 months (95% CI, 24.8–32.1 months) for high Ang-2 (p < 0.001). In contrast, higher Ang-1 was associated with longer OS. Median OS was 37.2 months (95% CI, 31.0–43.4 months) for high Ang-1 compared with 26.2 months (95% CI, 22.2–30.3 months) for those with low Ang-1 (p = 0.043). In conclusion, our findings indicate that plasma Ang-1 and Ang-2 levels are potential diagnostic and prognostic biomarkers in HCC.

Original languageEnglish (US)
Pages (from-to)37721-37732
Number of pages12
JournalOncotarget
Volume9
Issue number102
StatePublished - Dec 1 2018

Fingerprint

Angiopoietin-2
Angiopoietin-1
Hepatocellular Carcinoma
Survival
Confidence Intervals
Angiogenesis Inducing Agents
Healthy Volunteers
Biomarkers

Keywords

  • Angiogenesis
  • Angiopoietin-1
  • Angiopoietin-2
  • Cirrhosis
  • Hepatocellular carcinoma

ASJC Scopus subject areas

  • Oncology

Cite this

Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. / Pestana, Roberto Carmagnani; Hassan, Manal M; Ali, Reham Abdelwahab Hassan; Abugabal, Yehia I.; Girard, Lauren M.; Li, Donghui; Chang, Ping; Raghav, Kanwal Pratap Singh; Morris, Jeffrey; Wolff, Robert A; Rashid, Asif; Amin, Hesham; Kaseb, Ahmed.

In: Oncotarget, Vol. 9, No. 102, 01.12.2018, p. 37721-37732.

Research output: Contribution to journalArticle

@article{c8f1eb643523400a841883cec706999a,
title = "Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma",
abstract = "Angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) play critical roles in angiogenesis in hepatocellular carcinoma (HCC). In addition, recent data suggest that Ang-1/Ang-2 are involved in regulating the immune response. The aim of our study was to explore the clinical prognostic significance of plasma Ang-1 and Ang-2 in HCC. We prospectively enrolled and collected data and blood samples from 767 HCC patients treated at MD Anderson Cancer Center between 2001 and 2014. Controls consisted of cirrhotic patients (n = 75) and healthy volunteers (n = 200). The cutoff value was the median level of each angiogenic factor. Overall survival (OS) was estimated by Kaplan–Meier curves and compared by the log-rank test. Higher plasma Ang-2 was significantly associated with advanced clinicopathologic features of advanced HCC and lower OS. Median OS was 61.8 months (95{\%} confidence interval [CI], 45.1–78.5 months) for low Ang-2 compared with 28.5 months (95{\%} CI, 24.8–32.1 months) for high Ang-2 (p < 0.001). In contrast, higher Ang-1 was associated with longer OS. Median OS was 37.2 months (95{\%} CI, 31.0–43.4 months) for high Ang-1 compared with 26.2 months (95{\%} CI, 22.2–30.3 months) for those with low Ang-1 (p = 0.043). In conclusion, our findings indicate that plasma Ang-1 and Ang-2 levels are potential diagnostic and prognostic biomarkers in HCC.",
keywords = "Angiogenesis, Angiopoietin-1, Angiopoietin-2, Cirrhosis, Hepatocellular carcinoma",
author = "Pestana, {Roberto Carmagnani} and Hassan, {Manal M} and Ali, {Reham Abdelwahab Hassan} and Abugabal, {Yehia I.} and Girard, {Lauren M.} and Donghui Li and Ping Chang and Raghav, {Kanwal Pratap Singh} and Jeffrey Morris and Wolff, {Robert A} and Asif Rashid and Hesham Amin and Ahmed Kaseb",
year = "2018",
month = "12",
day = "1",
language = "English (US)",
volume = "9",
pages = "37721--37732",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "102",

}

TY - JOUR

T1 - Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma

AU - Pestana, Roberto Carmagnani

AU - Hassan, Manal M

AU - Ali, Reham Abdelwahab Hassan

AU - Abugabal, Yehia I.

AU - Girard, Lauren M.

AU - Li, Donghui

AU - Chang, Ping

AU - Raghav, Kanwal Pratap Singh

AU - Morris, Jeffrey

AU - Wolff, Robert A

AU - Rashid, Asif

AU - Amin, Hesham

AU - Kaseb, Ahmed

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) play critical roles in angiogenesis in hepatocellular carcinoma (HCC). In addition, recent data suggest that Ang-1/Ang-2 are involved in regulating the immune response. The aim of our study was to explore the clinical prognostic significance of plasma Ang-1 and Ang-2 in HCC. We prospectively enrolled and collected data and blood samples from 767 HCC patients treated at MD Anderson Cancer Center between 2001 and 2014. Controls consisted of cirrhotic patients (n = 75) and healthy volunteers (n = 200). The cutoff value was the median level of each angiogenic factor. Overall survival (OS) was estimated by Kaplan–Meier curves and compared by the log-rank test. Higher plasma Ang-2 was significantly associated with advanced clinicopathologic features of advanced HCC and lower OS. Median OS was 61.8 months (95% confidence interval [CI], 45.1–78.5 months) for low Ang-2 compared with 28.5 months (95% CI, 24.8–32.1 months) for high Ang-2 (p < 0.001). In contrast, higher Ang-1 was associated with longer OS. Median OS was 37.2 months (95% CI, 31.0–43.4 months) for high Ang-1 compared with 26.2 months (95% CI, 22.2–30.3 months) for those with low Ang-1 (p = 0.043). In conclusion, our findings indicate that plasma Ang-1 and Ang-2 levels are potential diagnostic and prognostic biomarkers in HCC.

AB - Angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) play critical roles in angiogenesis in hepatocellular carcinoma (HCC). In addition, recent data suggest that Ang-1/Ang-2 are involved in regulating the immune response. The aim of our study was to explore the clinical prognostic significance of plasma Ang-1 and Ang-2 in HCC. We prospectively enrolled and collected data and blood samples from 767 HCC patients treated at MD Anderson Cancer Center between 2001 and 2014. Controls consisted of cirrhotic patients (n = 75) and healthy volunteers (n = 200). The cutoff value was the median level of each angiogenic factor. Overall survival (OS) was estimated by Kaplan–Meier curves and compared by the log-rank test. Higher plasma Ang-2 was significantly associated with advanced clinicopathologic features of advanced HCC and lower OS. Median OS was 61.8 months (95% confidence interval [CI], 45.1–78.5 months) for low Ang-2 compared with 28.5 months (95% CI, 24.8–32.1 months) for high Ang-2 (p < 0.001). In contrast, higher Ang-1 was associated with longer OS. Median OS was 37.2 months (95% CI, 31.0–43.4 months) for high Ang-1 compared with 26.2 months (95% CI, 22.2–30.3 months) for those with low Ang-1 (p = 0.043). In conclusion, our findings indicate that plasma Ang-1 and Ang-2 levels are potential diagnostic and prognostic biomarkers in HCC.

KW - Angiogenesis

KW - Angiopoietin-1

KW - Angiopoietin-2

KW - Cirrhosis

KW - Hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85059358929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059358929&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85059358929

VL - 9

SP - 37721

EP - 37732

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 102

ER -